Dr. Benjamin Wolozin to Present "Development of Orally Available, Brain Penetrant Compound Reducing Tau Pathology" at CTAD 2023
CAMBRIDGE, Mass., Oct. 24, 2023 /PRNewswire/ -- Aquinnah Pharmaceuticals, leaders in stress granule biology that afflict a wide range of neurodegenerative disorders, today announced that the company's Co-Founder and Chief Scientific Officer, Dr. Benjamin Wolozin MD, Ph.D., will be presenting new preclinical research at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference. CTAD is the premier industry event highlighting new research and breakthroughs in the areas of disease-modifying agents, gene therapy, vaccines and multimodal interventions.